Jeligo (Linagliptin)

Linagliptin blocks the enzyme dipeptidyl peptidase‑4, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, linagliptin enhances insulin secretion and reduces glucagon release in a glucose‑dependent manner, improving overall glycaemic control.

The prescribed dose of Jeligo is determined by the treating physician based on the individual’s clinical condition, renal and hepatic function, and concomitant therapies. Patients should follow the exact dosing instructions provided by their healthcare professional.

Safety of linagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by the prescribing clinician.

To place an order, submit an enquiry on the Jeligo product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Jeligo (linagliptin) is a once‑daily DPP‑4 inhibitor that does not require dose adjustment in renal impairment, unlike some alternatives. Its efficacy in lowering HbA1c is comparable to other agents in the class, while its safety profile is similar, with low risk of hypoglycaemia when not combined with insulin or sulfonylureas.

Jeligo should be stored at ambient temperature, below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Jeligo is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should not crush, chew, or split the tablet unless specifically instructed by a healthcare professional.

Serious adverse events, although rare, include pancreatitis, severe allergic reactions such as anaphylaxis or angioedema, hepatic injury, bullous pemphigoid, and unexplained severe joint pain. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, or joint discomfort.

Jeligo is contraindicated in patients with a known hypersensitivity to linagliptin or any of its excipients. It should be used with caution in individuals with severe hepatic impairment, a history of pancreatitis, or those who are pregnant or breastfeeding unless clearly indicated by a physician.